Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson
-
Narrado por:
-
De:
In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).
Key Clinical Trials Discussed
1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL
2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL
3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)
4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL
5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL
6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL
7. Additional Studies Mentioned:
R-Pola-Glo Frail Study
DLBCL Classification